Home › Funds › FARALLON CAPITAL MANAGEMENT, L.L.C. › CRNX

FARALLON CAPITAL MANAGEMENT, L.L.C. position in CRNX

CRINETICS PHARMACEUTICALS IN

FARALLON CAPITAL MANAGEMENT, L.L.C. reported holding 8,989,098 shares of CRNX (CRINETICS PHARMACEUTICALS IN) in its Q2 2026 13F filing — a position valued at US$336.4M, representing 1.56% of its reported portfolio and ranking #22 among its reported holdings. FARALLON CAPITAL MANAGEMENT, L.L.C. has disclosed CRNX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)8.99M sh
Reported value held$336.37M
Portfolio Weight1.56%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How FARALLON CAPITAL MANAGEMENT, L.L.C.'s CRNX position evolved

FARALLON CAPITAL MANAGEMENT, L.L.C. first disclosed a stake in CRNX in Q3 2023 at 361,904 shares (US$10.8M). The position peaked in Q2 2026 at 8,989,098 shares, worth US$336.4M. Across 12 filings, FARALLON CAPITAL MANAGEMENT, L.L.C. increased the stake 9 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 8,989,098 shares valued at US$336.4M — an increase of 651,000 shares quarter over quarter.. Notable position changes include a 9840% increase in Q2 2024, a 134% increase in Q3 2024, a 251% increase in Q4 2024.

Quarter by quarter

QuarterSharesValueChange
Q3 2023 361.90K $10.76M New
Q4 2023 122.90K $4.37M Reduce
Q1 2024 5.00K $234.05K Reduce
Q2 2024 497.00K $22.26M Add
Q3 2024 1.16M $59.38M Add
Q4 2024 4.08M $208.36M Add
Q1 2025 4.61M $154.45M Add
Q2 2025 4.65M $133.62M Add
Q3 2025 5.77M $240.32M Add
Q4 2025 6.93M $322.74M Add
Q1 2026 8.34M $302.84M Add
Q2 2026 8.99M $336.37M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CRNX and 13F data

CRNX (CRINETICS PHARMACEUTICALS IN) is a company whose sector is not yet classified in our data. 37 other funds we track also report a position in CRNX — the largest reported positions include Farallon Capital Management (US$336.4M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$241.9M), Bellevue Group AG (US$98.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CRNX

All CRNX fund holders →

FAQ

How long has FARALLON CAPITAL MANAGEMENT, L.L.C. held CRNX?

FARALLON CAPITAL MANAGEMENT, L.L.C. has disclosed CRNX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is FARALLON CAPITAL MANAGEMENT, L.L.C.'s current position in CRNX?

As of Q2 2026, FARALLON CAPITAL MANAGEMENT, L.L.C. holds 8.99M shares of CRNX (CRINETICS PHARMACEUTICALS IN), valued at $336.37M, representing 1.56% of its reported portfolio and ranking #22.

Has FARALLON CAPITAL MANAGEMENT, L.L.C. been buying or selling CRNX?

In the latest 13F filing (Q2 2026), FARALLON CAPITAL MANAGEMENT, L.L.C. increased its position in CRNX. The position peaked in Q2 2026 at 8.99M shares.

Which other funds hold CRNX?

Other major institutional holders of CRNX include Farallon Capital Management, DRIEHAUS CAPITAL MANAGEMENT LLC, Bellevue Group AG, among 37 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.